Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.94, $3.38 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $5.24 million versus the consensus estimate of $6.3 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.